EUVIMEDEUVIMED entdecken
Crossref

Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel Therapies

Neali H Lucas iD, Jinzhong Liu, Aden Asefa, Ariel S Armstrong, Mary Thanh Hai

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Neali H Lucas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Drug Approval, Patient Selection, Racial Groups. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trial populations that are representative of the intended population for therapies build evidence supporting the generalizability of results to the intended population and improve adoption of novel therapies upon approval. We evaluated the demographic composition of trial populations in 62 pivotal studies supporting approval of novel therapies for human immunodeficiency virus, migraines, multiple sclerosis, and type 2 diabetes. Enrollment at all sites, US sites, and sites outside the United States was evaluated relative to US prevalence. Enrollment of Asian participants relative to US prevalence varied across evaluated drug programs. In most cases, enrollment of Black or African American participants across all sites combined was below disease prevalence. Enrollment for White participants was consistently above disease prevalence. For most programs, Hispanic or Latino participant enrollment met or approximated disease prevalence. For females, enrollment met or exceeded US prevalence in more than half of the therapies evaluated. Enrollment of Black or African American, White, and Hispanic or Latino participants from US sites in most trials approximated or exceeded US disease prevalence, whereas enrollment of Asian participants at US sites was generally below disease prevalence. Across evaluated trials, enrollment relative to disease prevalence varied at sites inside the United States compared to non‐US sites for Black and Asian participants. Enrollment by ethnicity, sex, or age group was generally similar for US and non‐US sites. Considering the demographics of countries where trial sites are located across development programs may enhance the ability to recruit participants that meaningfully reflect the population that would use therapies if approved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicDrug ApprovalPatient SelectionRacial GroupsHispanic or LatinoAdultAgedFemaleHumansMaleMiddle AgedAge FactorsDiabetes Mellitus, Type 2EthnicityHIV InfectionsMigraine DisordersMultiple SclerosisPrevalenceSex FactorsUnited States

Autor:innen und Institutionen

  • Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Neali H Lucas

Zitieren

APA

Lucas, N. H., Liu, J., Asefa, A., Armstrong, A. S., & Hai, M. T. (2025). Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel Therapies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3578

Vancouver

Lucas NH, Liu J, Asefa A, Armstrong AS, Hai MT. Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel Therapies. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3578

BibTeX
@article{Lucas2025,
  author = {Lucas, Neali H and Liu, Jinzhong and Asefa, Aden and Armstrong, Ariel S and Hai, Mary Thanh},
  title = {Analysis by Age, Sex, Race, and Ethnicity of Participants in Clinical Trials Supporting Recently Approved Novel Therapies},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3578}
}
Kostenlos starten →